Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819013 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT00819013 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 87 participants.
The verdict
NCT00819013, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered. Subjects will be randomized according to a randomization scheme.
Interventions
- BIOLOGICAL Saline placebo
- BIOLOGICAL Influenza A Vaccine: ACAM FLU-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00819013
The ClinicalTrials.gov registry entry for NCT00819013 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline placebo is the first listed.
NCT00819013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00819013 about?
NCT00819013 is a clinical study titled "Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults". This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered. Subjects will be randomized according to a randomization scheme.
What is the current status of trial NCT00819013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2007-07. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00819013?
The interventions under investigation include: Saline placebo (BIOLOGICAL), Influenza A Vaccine: ACAM FLU-A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00819013?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.